Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen

Transplant Immunology

Volumn 18, Issue 3, 2008, Pages 281-285

  Yang, Shun liang ^a,b   Wang, Dong ^b   Wu, Wei zhen ^b   Lin, Wen hong ^b   Xu, Ting zhao ^b   Cai, Jin quan ^b   Tan, Jian ming ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FUZHOU GENERAL HOSPITAL   (China)

Author keywords

ATG; Basiliximab; Induction therapy; Kidney transplantation; Sensitization

Indexed keywords

BASILIXIMAB; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ARTICLE; BACTERIAL INFECTION; BOLUS INJECTION; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; DRUG EFFICACY; DRUG SAFETY; FEVER; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MOUTH INFECTION; MYCOSIS; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; SERUM SICKNESS; SINGLE DRUG DOSE; SURVIVAL RATE; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VIRUS INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RECOMBINANT FUSION PROTEINS; TACROLIMUS;

EID: 36349011877     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2007.08.002     Document Type: Article

References (28)

1. Terasaki P.I., and Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 4 3 (2004) 438-443
2. Jordan S.C., Vo A.A., Peng A., Toyoda M., and Tyan D. Intravenous Gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 6 3 (2006) 459-466
3. Knight R.J., Kerman R.H., Schoenberg L., Podder H., Van Buren C.T., Katz S., et al. The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function. Transplantation 78 6 (2004) 904-910
4. Meier-Kriesche H.-U., Arndorfer J.A., and Kaplan B. Association of antibody induction with short-and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol 13 (2002) 769-772
5. Kaden J., Strobelt V., and May G. Short and long-term results after pretransplant high-dose single ATG-fresenius bolus in cadaveric kidney transplantation. Transplant Proc 30 (1998) 4011-4014
6. Abou J., and Almawi W. Intraoperative anti-thymocyte globulin-Fresenius (ATG-F) administration as induction immunosuppressive therapy in kidney transplantation. Mol Immunol 39 (2003) 1089-1094
7. Wang D., Chen J.H., Wu W.Z., Yang S.L., Wu G.J., Wang H., et al. One year results of preoperative single bolus ATG-Fresenius induction therapy in sensitized renal transplant recipients. Transplant Proc 39 1 (2007) 69-72
8. Mourad G., Rostaing L., Legendre C., Garrigue V., Thervet E., and Durand D. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 78 4 (2004) 584-590
9. Opelz G. Collaborative transplant study - 10-year report. Transplant Proc 24 (1992) 2342-2345
10. Gjertson D. A multi-factor analysis of kidney regraft outcomes. Clin Transpl (2002) 335-349
11. Takemoto S.K., Zeevi A., Feng S., Colvin R.B., Jordan S., Kobashigawa J., et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 4 7 (2004) 1033-1041
12. Vella J., and Neylan J. Why do we need induction therapy?. In: Sayegh M.H., and Remuzzi G. (Eds). Current and future immunosuppressive therapies following transplantation (2001), Kluwer Academic Publisher, Netherlands 187-204
13. Castro M.C., Araujo L.M., Nahas W.C., Arap S., David-Neto E., and Ianhez L.E. Induction versus noninduction therapy in kidney transplantation: considering different PRA levels and different induction therapies. Transplant Proc 36 4 (2004) 874-876
14. Jirasiritham S., Sumethkul V., Mavichak V., Lertsithichai P., and Jirasiritham S. The role of anti-IL-2 receptor in high-risk kidney transplant patients. Transplant Proc 36 7 (2004) 2110-2112
15. Mariat C., Afiani A., Alamartine E., Thibaudin D., de Filippis J.P., and Berthoux F. A pilot study comparing basiliximab and anti-thymocyte globulin as induction therapy in sensitized renal allograft recipients. Transplant Proc 33 7-8 (2001) 3192-3193
16. Thibaudin D., Alamartine E., de Filippis J.P., Diab N., Laurent B., and Berthoux F. Advantage of antithymocyte globulin induction in sensitized kidney recipients: a randomized prospective study comparing induction with and without antithymocyte globulin. Nephrol Dial Transplant 13 (1998) 711-715
17. Lebranchu Y., Bridoux F., Buchler M., Le Meur Y., Etienne I., Toupance O., et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2 1 (2002) 48-56
18. Abou-Jaoude M.M., Ghantous I., and Almawi W.Y. Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation. Mol Immunol 39 17-18 (2003) 1083-1088
19. Haririan A., Morawski K., Sillix D.H., El-Amm J.M., Garnick J., West M.S., et al. Induction therapy with basiliximab versus Thymoglobulin in African-American kidney transplant recipients. Transplantation 79 6 (2005) 716-721
20. Kahan B.D., Rajagopalan P.R., and Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation 67 (1999) 276-284
21. Brennan D.C. Thymoglobulin Induction Study Group. Thymoglobulin versus Simulect for induction immunosuppression in cadaveric renal transplant recipients: expanded results from a prospective, randomized, multicenter trial. Am J Transplant 3 Suppl 5 (2003) 438
22. Ducloux D., Kazory A., Challier B., Coutet J., Bresson-Vautrin C., Motte G., et al. Long-term toxicity of antithymocyte globulin induction may vary with choice of agent: a single-center retrospective study. Transplantation 77 (2004) 1029-1033
23. Opelz G., and Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 4 2 (2004) 222-230
24. Kaden J., May G., Strobelt V., Groth J., and Muller P. Intraoperative T-cell depletion prior to completion of anastomoses by high-dose single ATG bolus as a new approach to improve long-term results after kidney transplantation. Transplant Proc 29 1-2 (1997) 344-347
25. Yussim A., and Shapira Z. Single-bolus high-dose ATG for prophylaxis of rejection in renal transplantation-a prospective, randomized study. Transpl Int 13 S1 (2000) S293-S294
26. Abudher M.N., Moorhead J.F., Fernando O.N., and Varghese Z. Preoperative ATG bolus treatment increase CsA sensitivity of peripheral blood lymphocytes (PBLS) in renal transplant patients. Transplant Proc 31 8 (1999) 3361-3364
27. Nampoory M.R., Abdulhalim M., Johny K.V., Al-Jawad Donia F.A., Nair M.P., Said T., et al. Bolus anti-thymocyte globulin induction in renal transplant recipients: a comparison with conventional ATG or anti-interleukin-2 receptor antibody induction. Transplant Proc 34 7 (2002) 2916-2919
28. Goggins W.C., Pascual M.A., Powelson J.A., Magee C., Tolkoff-Rubin N., Farrell M.L., et al. A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 76 (2003) 798-802